What's New for the Patient With ER+/HER2- MBC Progressing on CDK 4/6 Inhibitor Therapy? Expert Perspectives on 2023 Updates From San Antonio

Join the experts for recent updates on estrogen receptor-positive (ER+)/HER2-negative (HER2-) metastatic breast cancer (MBC) progressing on cyclin-dependent kinase (CDK) 4/6 inhibitors.     Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/999406?ecd=bdc_podcast_libsyn_mscpedu